Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel B Salit

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Transplantation and Cellular Therapy|April 1, 2024
Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's PerspectiveRachel B Salit, Stephanie J Lee, Neel S Bhatt, et al.
Haematologica|November 17, 2018
Disability related to chronic graft -<i>versus</i>-host disease after alternative donor hematopoietic cell transplantationGiancarlo Fatobene, Barry E Storer, Rachel B Salit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2018
Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal CaregiversJessica Liang, Stephanie J Lee, Barry E Storer, et al.
Transplantation and Cellular Therapy|December 9, 2022
Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation StrategiesChristina K Ullrich, Kelsey K Baker, Paul A Carpenter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2020
High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral ProphylaxisElisabetta Xue, Hu Xie, Wendy M Leisenring, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 23, 2024
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple MyelomaRahul Banerjee, Andrew J Cowan, Marivel Ortega, et al.
Blood Advances|November 10, 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phaseVikas Gupta, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2017
Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant OutcomesBethany T Samuelson Bannow, Rachel B Salit, Barry E Storer, et al.
Bone Marrow Transplantation|May 21, 2024
Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantationKristin Rathje, Nico Gagelmann, Rachel B Salit, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Transplantation and Cellular Therapy|April 1, 2024
Returning to Work Following Hematopoietic Cell Transplantation: The Survivor's PerspectiveRachel B Salit, Stephanie J Lee, Neel S Bhatt, et al.
Haematologica|November 17, 2018
Disability related to chronic graft -<i>versus</i>-host disease after alternative donor hematopoietic cell transplantationGiancarlo Fatobene, Barry E Storer, Rachel B Salit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2018
Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal CaregiversJessica Liang, Stephanie J Lee, Barry E Storer, et al.
Transplantation and Cellular Therapy|December 9, 2022
Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation StrategiesChristina K Ullrich, Kelsey K Baker, Paul A Carpenter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignanciesRachel B Salit, Daniel H Fowler, Wyndham H Wilson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2020
High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral ProphylaxisElisabetta Xue, Hu Xie, Wendy M Leisenring, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 23, 2024
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple MyelomaRahul Banerjee, Andrew J Cowan, Marivel Ortega, et al.
Blood Advances|November 10, 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phaseVikas Gupta, James A Kennedy, Jose-Mario Capo-Chichi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 4, 2017
Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant OutcomesBethany T Samuelson Bannow, Rachel B Salit, Barry E Storer, et al.
Bone Marrow Transplantation|May 21, 2024
Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantationKristin Rathje, Nico Gagelmann, Rachel B Salit, et al.
Pageof 5